JP2022554267A - 組換えcdkl5タンパク質、遺伝子療法、及び製造方法 - Google Patents
組換えcdkl5タンパク質、遺伝子療法、及び製造方法 Download PDFInfo
- Publication number
- JP2022554267A JP2022554267A JP2022525193A JP2022525193A JP2022554267A JP 2022554267 A JP2022554267 A JP 2022554267A JP 2022525193 A JP2022525193 A JP 2022525193A JP 2022525193 A JP2022525193 A JP 2022525193A JP 2022554267 A JP2022554267 A JP 2022554267A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdkl5
- polypeptide
- fusion protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962928140P | 2019-10-30 | 2019-10-30 | |
| US201962928134P | 2019-10-30 | 2019-10-30 | |
| US62/928,140 | 2019-10-30 | ||
| US62/928,134 | 2019-10-30 | ||
| US202063090520P | 2020-10-12 | 2020-10-12 | |
| US63/090,520 | 2020-10-12 | ||
| PCT/US2020/058247 WO2021087282A1 (en) | 2019-10-30 | 2020-10-30 | Recombinant cdkl5 proteins, gene therapy and production methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554267A true JP2022554267A (ja) | 2022-12-28 |
| JP2022554267A5 JP2022554267A5 (cg-RX-API-DMAC7.html) | 2023-11-06 |
Family
ID=75716480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525193A Pending JP2022554267A (ja) | 2019-10-30 | 2020-10-30 | 組換えcdkl5タンパク質、遺伝子療法、及び製造方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230043046A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073231A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022554267A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220106981A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114901802A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020372988A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3156506A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202136514A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021087282A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| WO2022119890A1 (en) | 2020-12-01 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Compositions and uses thereof for treatment of angelman syndrome |
| KR20240100490A (ko) * | 2021-10-18 | 2024-07-01 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Cdkl5 결핍 장애(cdd)의 치료에 유용한 조성물 |
| WO2023077143A1 (en) * | 2021-11-01 | 2023-05-04 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of cdkl5 deficiency disorder (cdd) |
| AU2023288029A1 (en) * | 2022-06-21 | 2025-02-13 | Skyline Therapeutics Limited | Recombinant aav for the gene therapy of sma disease |
| CN116377050A (zh) * | 2022-12-16 | 2023-07-04 | 湖南家辉生物技术有限公司 | 一种发育性癫痫性脑病2型致病基因cdkl5突变位点的应用及其检测试剂和应用 |
| WO2025050032A1 (en) * | 2023-08-31 | 2025-03-06 | Ultragenyx Pharmaceutical Inc. | Methods of producing cdkl5 proteins and uses of the same |
| CN118638212B (zh) * | 2024-06-18 | 2025-07-04 | 河北绶肽生物科技有限公司 | 一种烟草表达的重组人源ⅲ型胶原蛋白及其编码基因和制备方法 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507655A (ja) * | 2014-02-28 | 2017-03-23 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | TATk−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用 |
| WO2018126112A1 (en) * | 2016-12-30 | 2018-07-05 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating phenylketonuria |
| WO2018129586A1 (en) * | 2017-01-10 | 2018-07-19 | Children's Medical Research Institute | Polynucleotides and vectors for the expression of transgenes |
| WO2019094253A1 (en) * | 2017-11-08 | 2019-05-16 | Avexis Inc. | Means and method for preparing viral vectors and uses of same |
| WO2019108924A2 (en) * | 2017-11-30 | 2019-06-06 | Amicus Therapeutics, Inc. | Cdkl5 expression variants and cdkl5 fusion proteins |
| JP2019522989A (ja) * | 2016-06-28 | 2019-08-22 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | TATκ−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2435562A1 (en) * | 2009-05-26 | 2012-04-04 | Biolex Therapeutics, Inc. | Compositions and methods for production of aglycosylated plasminogen |
| HRP20181315T1 (hr) * | 2010-11-22 | 2018-10-19 | Amicus Therapeutics, Inc. | Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| EP3632923A1 (en) * | 2015-01-16 | 2020-04-08 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| WO2017180587A2 (en) * | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2020191241A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| IT201900008877A1 (it) * | 2019-06-13 | 2020-12-13 | Univ Bologna Alma Mater Studiorum | Nuovi costrutti per terapia genica |
-
2020
- 2020-10-30 WO PCT/US2020/058247 patent/WO2021087282A1/en not_active Ceased
- 2020-10-30 JP JP2022525193A patent/JP2022554267A/ja active Pending
- 2020-10-30 AU AU2020372988A patent/AU2020372988A1/en not_active Abandoned
- 2020-10-30 EP EP20881783.3A patent/EP4073231A4/en not_active Withdrawn
- 2020-10-30 US US17/773,416 patent/US20230043046A1/en active Pending
- 2020-10-30 CN CN202080091287.7A patent/CN114901802A/zh active Pending
- 2020-10-30 CA CA3156506A patent/CA3156506A1/en active Pending
- 2020-10-30 TW TW109137883A patent/TW202136514A/zh unknown
- 2020-10-30 KR KR1020227018110A patent/KR20220106981A/ko not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017507655A (ja) * | 2014-02-28 | 2017-03-23 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | TATk−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用 |
| JP2019522989A (ja) * | 2016-06-28 | 2019-08-22 | アルマ マータ ステューディオラム — ユニバーシタ ディ ボローニャ | TATκ−CDKL5融合タンパク質、組成物、製剤、及びそれらの使用 |
| WO2018126112A1 (en) * | 2016-12-30 | 2018-07-05 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating phenylketonuria |
| WO2018129586A1 (en) * | 2017-01-10 | 2018-07-19 | Children's Medical Research Institute | Polynucleotides and vectors for the expression of transgenes |
| WO2019094253A1 (en) * | 2017-11-08 | 2019-05-16 | Avexis Inc. | Means and method for preparing viral vectors and uses of same |
| WO2019108924A2 (en) * | 2017-11-30 | 2019-06-06 | Amicus Therapeutics, Inc. | Cdkl5 expression variants and cdkl5 fusion proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020372988A1 (en) | 2023-06-01 |
| EP4073231A1 (en) | 2022-10-19 |
| CA3156506A1 (en) | 2021-05-06 |
| TW202136514A (zh) | 2021-10-01 |
| EP4073231A4 (en) | 2024-06-05 |
| KR20220106981A (ko) | 2022-08-01 |
| WO2021087282A1 (en) | 2021-05-06 |
| CN114901802A (zh) | 2022-08-12 |
| US20230043046A1 (en) | 2023-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020372988A1 (en) | Recombinant CDKL5 proteins, gene therapy and production methods | |
| CN113631182B (zh) | 二硫键稳定的多肽组合物和使用方法 | |
| US9840542B2 (en) | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells | |
| US20200299654A1 (en) | Cdkl5 expression variants and cdkl5 fusion proteins | |
| JP2021502058A (ja) | Rnaを編集するための組成物および方法 | |
| CN110337444B (zh) | 穿越血脑屏障的纳米药物载体 | |
| EA010055B1 (ru) | ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА | |
| US20170029798A1 (en) | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) | |
| AU2020316422A1 (en) | Multimeric protein domains for multifunctionality and enhanced secretion of therapeutic proteins | |
| Marcus et al. | Replacement of the C6ORF66 assembly factor (NDUFAF4) restores complex I activity in patient cells | |
| CA2903933C (en) | Methods and compositions for the packaging of nucleic acids into microglial exosomes for the targeted expression of polypeptides in neural cells | |
| US20150329609A1 (en) | Chimeric dystrophin proteins to treat dystrophinopathies | |
| WO2025038031A1 (en) | Engineered mitochondrion | |
| CN110785430A (zh) | 用于治疗纤维化和dna损伤介导的疾病的rage蛋白 | |
| US20230416315A1 (en) | Prion-fc region fusion protein and use thereof | |
| WO2025038955A9 (en) | Systems and methods for improving safety of split intein aav mediated gene therapy | |
| Yanez | Development of Non-Viral Vectors for Delivery of CRISPR/Cas9 to Treat Inherited Retinal Diseases | |
| RU2432359C2 (ru) | ПРИМЕНЕНИЕ СЛИТОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО БЕЛОК MeCP2 И ДОМЕН ТРАНСДУКЦИИ БЕЛКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ТАКОЙ БЕЛОК, И СПОСОБ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ СВЯЗАННОГО С РАЗВИТИЕМ НЕРВНОГО ЗАБОЛЕВАНИЯ | |
| KR20260028192A (ko) | 신경퇴행성 질환 및 장애의 치료 및 예방용 조성물 및 방법 | |
| KR20260068082A (ko) | Scn1a 관련 질환의 치료를 위한 스플릿 인테인의 사용 | |
| CN116554303A (zh) | 载脂蛋白E的C端片段及其在抑制γ分泌酶酶活中的应用 | |
| US20210381002A1 (en) | Gene therapy for oxidative stress | |
| KR20260008735A (ko) | 간상체-유래 원뿔세포 생존인자 및 인간 IgK 신호 서열을 인코딩하는 벡터 | |
| JP2026069482A (ja) | タウ凝集の阻害 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231026 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240917 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250311 |